Coatings anti-thrombogenic

On the basis of different effective longevities, anti-thrombogenic coatings are designed to adapt to variable blood-contacting durations. 

Pat. US., 4326532(1980). Anti-thrombogenic polymeric medical article, e.g. catheter. Having chitosan coating bonded to polymer and anti-thrombotic coating, e.g. heparin bonded to chitosan (Minnesota Mining Co.). 

Diagnostic and therapeutical treatments implicate the contact between tissue, blood and the implanted material. In the cardiovascular field, a variety of biomaterial is implanted in heart and vessels, such as catheters, stents, heart valves and sondes for pacemakers and defibrillators. Using polymers for new technologies has been a revolutionary advance in the therapy of cardiovascular disease [47]. Nevertheless, there is increasing evidence that the polymer coating could be responsible for adverse effects (e.g. in-stent-restenosis, stent thrombosis, chronicle foreign body reactions). Therefore, a feasible biocompatible material should provide a complete re-endothelialisation of the surface, less thrombogenicity as well as anti-inflammatory properties in order to improve clinical outcomes. 

---